Frontier Bio Corporation, an innovative pioneer in tissue engineering, has introduced a groundbreaking method for crafting living human blood vessels, ushering in a transformative era in medical device testing. The prevailing practice for assessing the safety and efficacy of vascular medical devices involves conducting animal studies before human trials. By harnessing lab-grown blood vessels, Frontier Bio is spearheading a future where dependence on animal testing is drastically minimized, if not eradicated.

Leveraging novel tissue engineering techniques, Frontier Bio manufactures blood vessels using biodegradable polymer scaffolds infused with vascular cells, fostering growth under biomimetic conditions within a laboratory setting. Employing 3D printing technology, Frontier Bio can fabricate these vessels in intricate shapes, replicating the natural architecture of blood vessels, and even simulating disease conditions.

The realm of gene therapy is ever-changing, with new possibilities and challenges continually emerging. With over 6,000 genetic disorders and the list growing, gene therapy stands as a potential panacea for monogenic diseases by altering an individual’s genetic makeup. Notable milestones, such as alipogene tiparvovec’s approval in 2012 and voretigene neparvovec’s endorsement in 2017, signified the transformative power of gene therapy. However, since these landmarks, the field has witnessed numerous developments and confronted its share of obstacles.

Gene Therapy: A Ray of Hope for Neuromuscular and Neurodegenerative Diseases

Neuromuscular diseases (NMDs) and neurodegenerative diseases (NDDs) are often progressive, life-shortening illnesses, many of which lack viable treatments. For this reason, NMDs and NDDs with genetic origins have become promising targets for gene therapy, aiming to address the root cause—the defective genes.

A significant turning point occurred in 2019 when the US Food and Drug Administration approved onasemnogene abeparvovec, an AAV therapy designed to combat spinal muscle atrophy (SMA). This marked a pivotal moment in NMD treatment. SMA, linked to mutations in the SMN1 gene, results in the gradual loss of motor neurons, leading to progressive muscle weakness and, in severe cases, respiratory failure. Onasemnogene abeparvovec involves delivering a functional copy of SMN1 via an AAV9 vector, administered through intravenous injection. Clinical trials showed improved functional and survival outcomes compared to the natural progression of the disease.